Related Experiment Video
Updated: May 7, 2026
09:43
Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts
Published on: August 1, 2025
Targeting fibroblast growth factor pathways in prostate cancer
Paul G Corn1, Fen Wang, Wallace L McKeehan
1Authors' Affiliations: The University of Texas MD Anderson Cancer Center; and Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, Texas.
Summary
Targeting the fibroblast growth factor (FGF) pathway offers a promising new treatment for advanced prostate cancer. Inhibiting FGF signaling may block tumor growth and spread, improving outcomes for patients with castrate-resistant disease.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Advanced prostate cancer has a poor prognosis, necessitating novel therapeutic strategies.
- Tumor progression and metastasis involve mechanisms like angiogenesis and cellular proliferation.
- The fibroblast growth factor (FGF) axis is implicated in prostate cancer development.
Purpose of the Study:
- To investigate the role of the FGF pathway in advanced prostate cancer progression.
- To evaluate the therapeutic potential of blocking the FGF pathway in castrate-resistant prostate cancer.
Main Methods:
- Analysis of aberrant FGF ligand and FGF receptor expression in prostate cancer.
- Investigating downstream signaling pathways activated by FGF, including MAPK, PI3K, and PLCγ.
- Clinical evaluation of small-molecule tyrosine kinase inhibitors (dovitinib, nintedanib) targeting the FGF pathway in Phase II trials.
Main Results:
- Aberrant FGF signaling drives key pathways promoting prostate cancer growth and metastasis.
- FGF pathway inhibition is being explored as a therapeutic strategy for advanced prostate cancer.
- Early clinical trial results indicate promise for FGF pathway inhibitors in castrate-resistant disease.
Conclusions:
- The FGF pathway is a critical driver of prostate cancer progression and metastasis.
- Therapeutic blockade of the FGF pathway, using inhibitors like dovitinib and nintedanib, shows potential for treating advanced prostate cancer.
- FGF pathway inhibition represents a promising novel strategy for castrate-resistant prostate cancer.
More Related Videos
Related Concept Videos
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:16TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
01:09Introduction to Fibroblasts
Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...